top of page

The Science: Complimentary Treatments

StiRx currently has a primary focus on a Gonococcal vaccine (STX-430/428) and gonococcal mAb (STX 426), with a chlamydia vaccine (STX-288) and other STI treatments in the exploratory phase of research.

science-graphics-30.png

Treatment as adjunctive therapy for antibiotic resistant N. gonorrhoeae for acute infections and high risk patients, or for topical application as preventative

science-graphics-17.png

Disease prevention in

all at-risk patient populations

bottom of page